Cultivated Meat & Cellular Agriculture

Cultivated meat has moved from concept to commercial in the US and Singapore with multiple FDA 'no questions' letters. The session covers Upside Foods, Good Meat, BlueNalu and Wildtype commercial launches, scale-up economics and the path to cost parity, scaffold engineering for structured products, bioreactor design for industrial-scale animal-cell culture, regulatory frameworks post-FDA letters and the EU EFSA pathway, and consumer-acceptance research across markets. Discussion addresses media and serum-free formulations, life-cycle assessment vs conventional meat, GMP-grade cell-line development, regulatory dual-track in EU and Asia, and the long-term economic viability question that defines the next five years for the industry.